CO5140117A1 - Benzamide derivatives therapeutic - Google Patents

Benzamide derivatives therapeutic

Info

Publication number
CO5140117A1
CO5140117A1 CO99075519A CO99075519A CO5140117A1 CO 5140117 A1 CO5140117 A1 CO 5140117A1 CO 99075519 A CO99075519 A CO 99075519A CO 99075519 A CO99075519 A CO 99075519A CO 5140117 A1 CO5140117 A1 CO 5140117A1
Authority
CO
Colombia
Prior art keywords
c1
alkyl
radicals
ring
c2
Prior art date
Application number
CO99075519A
Other languages
Spanish (es)
Inventor
Alain Claude-Marie Daugan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9826412.0A priority Critical patent/GB9826412D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO5140117A1 publication Critical patent/CO5140117A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Abstract

Un compuesto de fórmula (I)<EMI FILE="99075519_1" ID="1" IMF=JPEG >en dondeA representa N ó CH;X se selecciona de los siguientes grupos:(i) -C1-6alquileno-, opcionalmente conteniendo uno o dos enlaces dobles y opcionalmente substituido por uno o más grupos hidroxi, alquilo, C1-6, alcoxi C1-6, acilo C1-6 o aciloxi C1-6,(ii) oxo, sulfonilo, tioxo,(iii) -C1-6alquilencarbonilo-, -C1-6alquilensulfonilo-,-C1-6alquilentioxo,(iv) -C2-6alquilenoxi, -C2-6alquilentio-, C2-6alquilen(NH ó N-C1-6alquil)amino-,(v) -C1-6alquilencarboxi-, -C1-6alquilentioamido-, -C1-6alquilen(NH ó N-C1-6alquil)carboxiamido-, y(vi) -C2-6alquilenoxicarbonil-, -C2-6alquilentiocarbonil-,-C2-6 alquilen(NH ó N-C1-6alquil)aminocarbonilo-;Z representa un enlace directo o -C1-6alquileno-, opcionalmente conteniendo un enlace doble y opcionalmente substituido por uno o más grupos hidroxi, alquilo C1-6, alcoxi C1-6, acilo C1-6 o aciloxi C1-6;R1 se selecciona de los siguientes grupos:(i) hidrógeno, C1-3 perfluoroalquilo,(ii A compound of formula (I) <EMI FILE = "99075519_1" ID = "1" MFI = JPEG> in dondeA represents N or CH; X is selected from the following groups: (i) -C1-6alquileno-, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, alkyl, C1-6, C1-6 alkoxy, C1-6 acyl or C1-6 acyloxy, (ii) oxo, sulfonyl, thioxo, (iii) -C1- 6alquilencarbonilo-, -C1-6alquilensulfonilo -, - C1-6alquilentioxo, (iv) -C2-6alquilenoxi, -C2-6alquilentio-, C2-6alquilen (NH or N-C1-6alkyl) amino -, (v) -C1-6alquilencarboxi -, -C1-6alquilentioamido-, -C1-6alquilen (NH or N-C1-6alkyl) carboxyamido-, and (vi) -C2-6alquilenoxicarbonil-, -C2-6alquilentiocarbonil -, - C2-6 alkylene (NH or N- C 1-6 alkyl) aminocarbonyl-; Z represents a direct bond or -C1-6alquileno- optionally containing a double bond and optionally substituted by one or more hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl or acyloxy C1-6alkyl; R1 is selected from the following groups: (i) hydrogen, C1-3 perfluoroalkyl, (ii ) arilo C6-10, cicloalquilo C3-8 y derivados benzo de fusión de los mismos, policicloalquilo C7-10, cicloalquenilo C4-8, policicloalquenilo C7-10,(iii) un heterociclilo del grupo que consiste de radicales monocíclicos y radicales policíclicos fundidos, en donde los radicales contienen un total de 5-14 átomos en el anillo, en donde los radicales contienen un total de 1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, y en donde los anillos individuales de los radicales pueden ser independientemente saturados, parcialmente insaturados o aromáticos y (iv) en donde X es alquileno C1-6 y Z es un enlace directo, o Z es alquileno C1-6, R1 puede representar adicionalmente un grupo halógeno, ciano, nitro o acilo C1-6,en donde cuando R1 contiene uno o más anillos, los anillos pueden cada uno independientemente soportar de 0 a 4 substituyentes independientemente seleccionados de(i) halógeno, hidroxi, ciano, nitro, formilo, alquilsulfonilamino ) C6-10 aryl, C3-8cycloalkyl and benzo derivatives fusion thereof, C7-10 polycycloalkyl, C4-8 cycloalkenyl, C7-10 polycycloalkenyl, (iii) a heterocyclyl group consisting of monocyclic radicals and fused polycyclic radicals , wherein the radicals contain a total of 5 to 14 ring atoms, wherein the radicals contain a total of 1-4 heteroatoms independently ring selected from oxygen, nitrogen and sulfur, and wherein the individual rings of the radicals may independently be saturated, partially unsaturated or aromatic and (iv) wherein X is C1-6 alkylene and Z is a direct bond, or Z is C1-6 alkylene, R1 may additionally represent halogen, cyano, nitro or acyl C1 -6, wherein when R1 contains one or more rings, the rings may each independently bear 0 to 4 substituents independently selected from (i) halogen, hydroxy, cyano, nitro, formyl, alkylsulfonylamino -C1-6,- 2 - (ii) alquilo C1-6, cicloalquilo C3-8, perfluoroalquilo C1-3,(iii) alcoxi C1-6, metilendioxi, perfluoroalcoxi C1-3, alquiltio C1-6,(iv) amino, alquilamino C1-6, dialquilamino C1-6,(v) fenilo, fenoxi, feniltio, halofeniltio, bencilo, benciloxi,(vi) hidroxicarbonilo, C1-6alcoxicarbonilo,(vii) aminocarbonilo, alquilaminocarbonilo C1-6, dialquilaminocarbonilo C1-6, dialquilaminocarbonilo C1-6 aIcoxi C1-6, perfluoroalquilaminocarbonilo C1-3,(viii) acilo C1-6, aciloxi C1-6, aciloxi C1-6 alquilo C1-6, acilamino C1-6, y(ix) un heterociclilo aromático que consiste de radicales monocíclicos en donde los radicales contienen de 5-6 átomos en el anillo, en donde los radicales contienen un total de 1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, y en donde cada uno de los grupos heterociclilo está opcionalmente substituido por uno o más grupos seleccionados independientemente de halógeno, alquilo C1-4, alcoxi C1-4, perfluoroalquilo -C1-6 - 2 - (ii) C1-6 alkyl, C3-8 cycloalkyl, C1-3 perfluoroalkyl, (iii) C1-6 alkoxy, methylenedioxy, C1-3 perfluoroalkoxy, C1-6 alkylthio, (iv) amino , C1-6 alkylamino, C1-6 dialkylamino, (v) phenyl, phenoxy, phenylthio, halofeniltio, benzyl, benzyloxy, (vi) hydroxycarbonyl, C1-6 alkoxycarbonyl, (vii) aminocarbonyl, C1-6 alkylaminocarbonyl, C1-6 dialkylaminocarbonyl, C1-6 dialkylaminocarbonyl C1-6 aIcoxi, C1-3 perfluoroalquilaminocarbonilo, (viii) C1-6 acyl, acyloxy C1-6, C1-6 acyloxy C1-6 alkyl, C1-6 acylamino, and (ix) an aromatic heterocyclyl consisting monocyclic radicals where radicals contain 5-6 ring atoms, wherein the radicals contain a total of 1-4 heteroatoms independently ring selected from oxygen, nitrogen and sulfur, and wherein each heterocyclyl groups is optionally substituted by one or more groups independently selected from halogen, C1-4 alkyl, C1-4 alkoxy, perfluoroalkyl C1-3, y perfluoroalcoxi C1-3;Y representa una ligadura oxi o directa, -alquileno C1-6-, -oxialquilenoC1-6, o un heterociclilo consistente de radicales monocíclicos, en donde los radicales contienen 5 átomos en el anillo, y en donde los radicales contienen un total de 1-4 heteroátomos en el anillo seleccionados independientemente de oxígeno, nitrógeno y azufre, y en donde el anillo puede estar independientemente saturado, parcialmente insaturado o aromático;R2 representa fenilo, cicloalquilo C3-8 o heterociclilo consistente de radicales monocíclicos en donde los radicales contienen un total de 5-6 átomos en el anillo, en donde los radicales contienen un total de1-4 heteroátomos en el anillo independientemente seleccionados de oxígeno, nitrógeno y azufre, en donde el anillo puede ser independientemente saturado, parcialmente insaturado o aromático; C1-3 and C1-3 perfluoroalkoxy; Y represents a direct bond or oxy, -C 1-6 alkyl-, -oxialquilenoC1-6, or heterocyclyl consisting of monocyclic radicals, wherein the radicals contain 5 ring atoms, and wherein the radicals contain a total of 1-4 heteroatoms independently oxygen, nitrogen and sulfur ring and wherein the ring may be independently saturated, partially unsaturated or aromatic; R2 represents phenyl, C3-8 cycloalkyl or heterocyclyl consisting monocyclic radicals wherein the radicals contain a total of 5-6 ring atoms, wherein the radicals contain a total de1-4 heteroatoms independently ring selected from oxygen, nitrogen and sulfur, wherein the ring may be independently saturated , partially unsaturated or aromatic; y en donde cada R2 está opcionalmente substituido por uno o más grupos independientemente seleccionados de halógeno, alquilo C1-4, alcoxi C1-4, cicloalquilo C3-8, perfluoroalquilo C1-3, perfluoroalcoxi C1-3, hidroxicarbonilo, alcoxicarbonilo C1-6, ciano, nitro, alquilaminosulfonilo;R3 representa hidrógeno o uno o más grupos seleccionados independientemente de halógeno, alquilo C1-4, alcoxi C1-4, perfluoroalquilo C1-3, o perfluoroalcoxi C1 -3; and wherein each R2 is optionally substituted by one or more groups independently selected from halogen, C1-4 alkyl, C1-4 alkoxy, C3-8 cycloalkyl, C1-3 perfluoroalkyl, perfluoroalkoxy C1-3, hydroxycarbonyl, C1-6alkoxycarbonyl, cyano, nitro, alkylaminosulfonyl; R3 represents hydrogen or one or more groups independently selected from halogen, C1-4 alkyl, C1-4 alkoxy, C1-3 perfluoroalkyl, perfluoroalkoxy or C1 -3; o una sal fisiológicamente aceptable, solvato o derivado de la misma. or a physiologically acceptable salt, solvate or derivative thereof.
CO99075519A 1998-12-03 1999-12-01 Benzamide derivatives therapeutic CO5140117A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9826412.0A GB9826412D0 (en) 1998-12-03 1998-12-03 Chemical compounds

Publications (1)

Publication Number Publication Date
CO5140117A1 true CO5140117A1 (en) 2002-03-22

Family

ID=10843463

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99075519A CO5140117A1 (en) 1998-12-03 1999-12-01 Benzamide derivatives therapeutic

Country Status (21)

Country Link
US (1) US6552022B1 (en)
EP (1) EP1135378A1 (en)
JP (1) JP2002531444A (en)
CN (1) CN1131222C (en)
AR (1) AR021434A1 (en)
AU (1) AU750259B2 (en)
BR (1) BR9915895A (en)
CA (1) CA2353394A1 (en)
CO (1) CO5140117A1 (en)
CZ (1) CZ20011973A3 (en)
GB (1) GB9826412D0 (en)
HU (1) HU0104497A3 (en)
IL (1) IL142913D0 (en)
NO (1) NO20012688D0 (en)
NZ (1) NZ511481A (en)
PE (1) PE15622000A1 (en)
PL (1) PL348042A1 (en)
TR (1) TR200101513T2 (en)
TW (1) TW515796B (en)
WO (1) WO2000032582A1 (en)
ZA (1) ZA200103680B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
US6878707B2 (en) 2000-01-18 2005-04-12 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Polyarylcarboxamides useful as lipid lowering agents
IL155196D0 (en) * 2000-10-05 2003-11-23 Fujisawa Pharmaceutical Co Benzamide derivatives and pharmaceutical compositions containing the same
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Biphenylcarboxamides useful as lipid lowering agents
DE10101150A1 (en) 2001-01-12 2002-07-18 Bayer Ag A process for the preparation of trifluoromethyl-substituted biphenylcarboxylic acids and new trichloromethyl and trifluoromethyl-substituted biphenylcarbonitriles
JP2004520347A (en) * 2001-01-15 2004-07-08 グラクソ グループ リミテッドGlaxo Group Limited Ldl- aryl piperidine and piperazine derivatives as inducers of receptor expression
WO2002055495A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2002055497A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Lipid lowering biphenulcarboxamides
GB0109287D0 (en) * 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
CA2468716A1 (en) * 2001-11-28 2003-06-05 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
BR0209932A (en) * 2001-05-22 2004-10-13 Neurogen Corp The compound or pharmaceutically acceptable salt thereof, pharmaceutical composition, packaged pharmaceutical preparation, methods for modulating binding of MCH to a MCH receptor and mvc to alter the signal-transducing activity of a MCH receptor in a cell, to treat a disease or disorder associated with pathogenic obesity MCH receptor activation and determine the presence or absence of MCH receptor in a sample, and use of a compound
EP1935885A3 (en) * 2001-05-22 2008-10-15 Neurogen Corporation Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
WO2002098839A1 (en) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
GB0129013D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
RU2293721C2 (en) 2002-02-28 2007-02-20 Джапан Тобакко Инк. Ester compounds and their using in medicine
EG25699A (en) 2002-08-12 2012-05-22 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
JP4832897B2 (en) 2003-08-29 2011-12-07 日本たばこ産業株式会社 Ester derivatives and their pharmaceutical use
EA009081B1 (en) * 2003-12-09 2007-10-26 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
JO2537B1 (en) * 2004-03-10 2010-09-05 جانسين فارماسوتيكا ان. في MTP inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AR051092A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as inhibitors of stearoyl-coa
MX2007003319A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Pyridazine derivatives for inhibiting human stearoyl-coa- desaturase.
AR051202A1 (en) 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as inhibitors of stearoyl coa desaturase-
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
WO2007053436A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
BRPI0717314A2 (en) * 2006-10-24 2014-01-21 Janssen Pharmaceutica Nv acid derivatives tetrahydro-naphthalene-1-carboxylic MTP inhibitors
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
PE03622009A1 (en) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Piperidine derivatives / piperazine as modulators of DGAT
JP5579170B2 (en) 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Drug combinations containing the Dgat inhibitor and ppar agonist
JO2972B1 (en) * 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
US20110144107A1 (en) * 2008-06-11 2011-06-16 Irm Llc Compounds and compositions useful for the treatment of malaria
EP2523664A4 (en) * 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc Compounds and methods
AR109304A1 (en) 2016-08-10 2018-11-21 Sumitomo Chemical Co Oxadiazole compound and its use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES291187A1 (en) * 1963-04-04 1964-01-16 American Cyanamid Co A process for preparing substituted piperazines
US4022900A (en) 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
DK0533268T3 (en) * 1991-09-18 2001-12-03 Glaxo Group Ltd Benzanilide derivatives as 5-HT 1D antagonists
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
GB9119920D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
EA001539B1 (en) 1996-11-27 2001-04-23 Пфайзер Инк. Amides ingibiting secretion of b apolyprotein (apo b) and/or microsome protein triglycerides transfer (mtr)

Also Published As

Publication number Publication date
CN1334808A (en) 2002-02-06
NZ511481A (en) 2003-11-28
CA2353394A1 (en) 2000-06-08
US6552022B1 (en) 2003-04-22
AR021434A1 (en) 2002-07-17
NO20012688D0 (en) 2001-05-31
ZA200103680B (en) 2002-06-14
TR200101513T2 (en) 2001-10-22
CN1131222C (en) 2003-12-17
NO20012688L (en) 2001-05-31
IL142913D0 (en) 2002-04-21
PE15622000A1 (en) 2001-01-26
BR9915895A (en) 2001-08-21
AU750259B2 (en) 2002-07-11
HU0104497A3 (en) 2002-07-29
CZ20011973A3 (en) 2001-09-12
JP2002531444A (en) 2002-09-24
PL348042A1 (en) 2002-05-06
AU1656600A (en) 2000-06-19
WO2000032582A1 (en) 2000-06-08
GB9826412D0 (en) 1999-01-27
EP1135378A1 (en) 2001-09-26
HU0104497A2 (en) 2002-05-29
TW515796B (en) 2003-01-01

Similar Documents

Publication Publication Date Title
RU2329263C2 (en) Derivative of imide indolylmaleic acid as an inhibitor of proteinkinase c
TWI222973B (en) Novel heterocyclic compounds with interferon inducers and pharmaceutical composition comprising the same
EA200000481A1 (en) The hydroxamic acid derivatives as inhibitors of matrix metalloproteases (MMM)
PE06362004A1 (en) Ester 2&#39;-methyl-3&#39;-c-ol-Valine ribofuranosilcitidina
ES2123264T3 (en) 2 - ((dihydro) pyrazolyl-3&#39;-oxymethylene) are -anilidas as pesticides and fungicides.
CO4960641A1 (en) Piperidine derivatives 1,4-disubstituted fluorine-containing
CY1107886T1 (en) KINASE INHIBITORS AS THERAPEUTIC AGENTS
PA8539401A1 (en) Quinazolines as inhibitors of MMP-13
CO4810382A1 (en) Indole compounds anti-inflammatory / analgesic agents
ES2196396T3 (en) heteroaromatics containing 5-membered oxygen or sulfur as factor Xa inhibitors.
AR034244A1 (en) Derivatives 4-aminopiperidine and their use as medicaments
AR029634A1 (en) derivatives heterocyclic compounds useful as anticancer agents, pharmaceutical composition and method of treatment
AR016817A1 (en) Phenylurea derivatives or phenylthiourea, process for their preparation, collection of compounds, intermediate compounds, pharmaceutical composition, method of treatment and use of said compounds for the manufacture of a medicament
AR012315A1 (en) Dithiolane derivatives and their use in the manufacture of a medicament.
ES2160408T3 (en) Trifluorophenyl-triazolopyrimidines fungicides.
ES2178037T3 (en) Cyclosporin derivatives, their preparation and pharmaceutical compositions containing them.
CO5570660A2 (en) Indazolilpirrolotriazinas c-6 modified
NZ512864A (en) Triazole compounds with dopamine-D3-receptor affinity
CY1112760T1 (en) Polycyclic derivatives indazolis which is INHIBITORS toy erk
AR036608A1 (en) Imidazole derivatives, pharmaceutical compositions and use of said derivatives for the manufacture of a medicament for the treatment of obesity
AR241014A2 (en) Process for the preparation of phenylethanoaminotetralines with lipolytic activity
AR035804A1 (en) novel tyrosine kinase inhibitors
CY1111648T1 (en) Polyarylcarboxamide USEFUL AS FACTORS REDUCING LIPID
AR038536A1 (en) N-aryl-2-oxazolidinone-5- carboxamides and derivatives
SE8406200L (en) indole derivatives